Interim Report January - June 2003

Report this content

BIOINVENT INTERIM REPORT 1 JANUARY - 31 MARCH 2003 q Acquisition of drug project in the cancer field from research group at the Karolinska Institute in Stockholm, Sweden. q So far six target structures have been accepted into the collaboration with Oxford GlycoSciences. q Patent applications submitted within the framework of the collaboration with GlaxoSmithKline and within the Protein array field. q q Net revenue for January - March 2003: SEK 16.8 million (18.0). Loss after net financial items for January - March 2003: SEK -20.8 million (-11.7). q q Cash flow from current operations and investment activity for January - March 2003: SEK -17.8 million (24.4). Liquid funds at year end: SEK 325.7 million (363.1). q Contact: Any questions regarding this report will be answered by: Svein Mathisen, President and CEO, +46 (0)46 286 85 67, mobile +46 (0)708 97 82 12 or Jonas Källmén, CFO, +46 (0)46 286 38 12, mobile +46 (0)708 77 48 07. The report is also available at www.bioinvent.com BioInvent International AB (publ.) Co. reg. no. 556537-7263 ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00640/wkr0002.doc The full report http://www.waymaker.net/bitonline/2003/09/25/20030925BIT00640/wkr0003.pdf The full report

Subscribe

Documents & Links